Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4095-4102

  Wysocki, Piotr J ^a   Kwiatkowska, Eliza P ^a   Kazimierczak, Urszula ^a   Suchorska, Wiktoria ^a   Kowalczyk, Dariusz W ^a   Mackiewicz, Andrzej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; KIDNEY CANCER; LYMPHOCYTIC INFILTRATION; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; SARCOMA, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746074464     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2489     Document Type: Article

References (44)

1. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. Arch Intern Med 1994;154:513-23.
2. Martin MFR, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet 1984;8390:1325-8.
3. Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP. Angiotensin- converting enzyme inhibitor therapy and diabetic retinopathy. Ann Opthalmol 1992;24:99-103.
4. Collins R, Peto R, Flather M, et al. ISIS-4A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
5. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol 1994;43:151-63.
6. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension (Dallas) 1990;15:327-31.
7. Ashab I, Peer G, Blum M, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995;47:1515-21.
8. Lewis EJ. Captopril and diabetic nephropathy. J Am Med Assoc 1995;273:1831.
9. Ward WF, Kim YT, Molteni A, Solliday NH. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1988;15:135-40.
10. Ward WF, Molteni A, Ts'ao C, Hinz JM. The effect of captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990;63:349-54.
11. Le Noble FA, Schreurs NH, van Straaten HW, et al. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 1993;264:460-5.
12. Le Noble FA, Hekking JW, Van Straaten HW, Slaaf DW, Struyker Boudier HA. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 1991;195:305-6.
13. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-8.
14. Yoshiji H, Yoshii J, Ikenaka Y, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002;6:1227-31.
15. Norman J, Badie-Dezfooly B, Nord EP, et al. EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 1987;253:299-309.
16. Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990;259:768-77.
17. Wolf G, Ziyadeh FN, Helmchen U, Zahner G, Schroeder R, Stahl RA. ANG II is a mitogen for a murine cell line isolated from medullary thick ascending limb of Henle's loop. Am J Physiol 1995;268:940-7.
18. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-84.
19. Ronquist G. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004;58:50-6.
20. Molteni A, Ward WF, Ts'ao CH, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 2003;9:751-61.
21. Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr Pharm Des 2003;9:723-35.
22. Heeger PS, Valujskikh A, Lehmann PV. Comprehensive assessment of determinant specificity, frequency, and cytokine signature of the primed CD8 cell repertoire induced by a minor transplantation antigen. J Immunol 2000;165:1278-84.
23. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
24. Gambotto A, Dworacki G, Cicinnati V, et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 2000;7:2036-40.
25. Kowalczyk DW, Wlazlo AP, Shane S, Ertl HC. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine 2001;19:3583-90.
26. Weiss J, Zimmermann F. Tribromoethanol (Avertin) as an anaesthetic in mice. Lab Anim 1999;33:192-3.
27. Ahn KS, Jung YS, Kim J, Lee H, Yoon SS. Behavior of murine renal carcinoma cells grown in ectopic or orthotopic sites in syngeneic mice. Tumor Biol 2001;22:146-53.
28. Vieweg J, Heston WD, Gilboa E, Fair WR. An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer. Prostate 1994;6:291-8.
29. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
30. Small W, Jr., Molteni A, Kim YT, Taylor JM, Ts'ao CH, Ward WF. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res Treat 1999;55:223-9.
31. Linehan WM, Shipley WU, Parkinson DR. Cancer of the kidney and urether. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 858-911.
32. Delfraissy JF, Galanaud P, Balavoine JF, Wallon C, Dormont J. Captopril and immune regulation. Kidney Int 1984;6:925-9.
33. Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol 2000;3:515-22.
34. Yeung JH. A comparison of the effects of angiotensin-converting enzyme inhibitors with bradykinin, angiotensin II and their specific antagonists on concanavalin A-induced proliferation of mouse T-lymphocytes. Methods Find Exp Clin Pharmacol 1994;3:163-72.
35. Constantinescu CS, Goodman DBP, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998;62:25-31.
36. Olausson M, Mjornstedt L, Wramner L, Herlitz H. Effect of captopril treatment on allograft survival and induction of unresponsiveness in heart-transplanted, ATG-treated rats. Nephrol Dial Transplant 1992;11:1130-2.
37. + T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003;197:927-32.
38. Huang AY, Golumbek P, Ahmadzedeh M, Haffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
39. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997;158:2834-42.
40. Qin Z, Richter G, Schuler T, Ibe S, Cao Z, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
41. Croft M. Activation of naive, memory and effector T cells. Curr Opin Immunol 1994;6:431-7.
42. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
43. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:242-52.
44. Lapteva N, Ide K, Nieda M, et al. Activation and suppression of renin-angiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002;296:194.